| Literature DB >> 32828387 |
Kari Tanderup1, Nicole Nesvacil2, Kathrin Kirchheiner2, Monica Serban3, Sofia Spampinato4, Nina Boje Kibsgaard Jensen4, Maximilian Schmid2, Stephanie Smet5, Henrike Westerveld6, Stefan Ecker2, Umesh Mahantshetty7, Jamema Swamidas8, Supriya Chopra8, Remi Nout9, Li Tee Tan10, Lars Fokdal4, Alina Sturdza2, Ina Jürgenliemk-Schulz9, Astrid de Leeuw11, Jacob Christian Lindegaard4, Christian Kirisits2, Richard Pötter2.
Abstract
The last 2 decades have witnessed the development and broad adoption of image-guided adaptive brachytherapy (IGABT) combined with radiochemotherapy in patients with locally advanced cervical cancer. A variety of brachytherapy techniques and dose/fractionation schedules have been applied, and until recently, there was no strong evidence available for preferring one approach to another. However, large volumes of data have now provided high level clinical evidence for dose-effect relations for both disease and morbidity endpoints. It is therefore now possible to apply evidence based dose planning aims and dose prescription protocols in IGABT for locally advanced cervical cancer. This review gives an overview of targets/organs-at-risk and disease/morbidity endpoints which are relevant in the context of treatment planning and dose prescription in IGABT. The dosimetric and clinical evidence is summarized to support the implementation of dose prescription protocols which include hard and soft constraints for targets and organs at risk.Entities:
Year: 2020 PMID: 32828387 DOI: 10.1016/j.semradonc.2020.05.008
Source DB: PubMed Journal: Semin Radiat Oncol ISSN: 1053-4296 Impact factor: 5.934